Grifols, S.A. (GIFOF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Grifols, S.A. (GIFOF) Healthcare & Pipeline Overview

Grifols, S.A. is a prominent player in the healthcare sector, specializing in the development and manufacturing of plasma-derived therapies and diagnostic products, with a commitment to addressing the needs of patients with chronic and rare diseases.

What Is the Investment Thesis for GIFOF?

Grifols, S.A. presents a solid investment thesis driven by its strong market position in the plasma-derived medicines sector, which is projected to grow significantly due to increasing demand for therapies addressing chronic and rare diseases. The company boasts a market capitalization of $8.70B and a P/E ratio of 14.7, indicating a favorable valuation relative to its earnings potential. With a profit margin of 5.6% and a gross margin of 37.7%, Grifols demonstrates operational efficiency that supports its profitability. The ongoing expansion of its product portfolio and the increasing prevalence of conditions requiring hemoderivatives position Grifols for sustained revenue growth. Additionally, the company's focus on innovation and strategic partnerships will likely enhance its competitive advantage. However, investors should remain cautious of potential risks, including patent expirations and competition from biosimilars, which could impact future earnings.

Based on FMP financials and quantitative analysis

GIFOF Key Highlights

Market capitalization of $8.70B reflects strong positioning in the healthcare sector.

• P/E ratio of 14.7 indicates a competitive valuation compared to industry peers.
• Profit margin of 5.6% demonstrates operational efficiency and effective cost management.
• Gross margin of 37.7% exceeds industry averages, highlighting product profitability.
• Dividend yield of 1.66% provides a return to shareholders amidst growth initiatives.

Who Are GIFOF's Competitors?

GIFOF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GIFOF's Key Strengths?

Strong market position in plasma-derived therapies.

• Diverse product portfolio catering to various medical needs.
• Robust R&D capabilities driving innovation.
• Established global presence with a wide customer base.

What Are GIFOF's Weaknesses?

Exposure to patent expiration risks.

• Dependence on the plasma supply chain for production.
• Potential regulatory challenges in different markets.
• Limited presence in certain emerging markets compared to competitors.

What Could Drive GIFOF Stock Higher?

Expansion into emerging markets expected to drive revenue growth over the next five years.

• Continuous development of innovative plasma-derived therapies to meet increasing patient demand.
• Strategic partnerships enhancing R&D capabilities and product offerings.
• Anticipated regulatory approvals for new diagnostic products in the pipeline.
• Focus on sustainability initiatives to improve brand reputation and attract investors.

What Are the Key Risks for GIFOF?

Financial-distress signal — its Altman Z-Score of 1.13 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Exposure to patent expirations affecting product exclusivity and revenue.
• Competition from biosimilars and other pharmaceutical companies impacting market share.
• Regulatory changes that could affect product approvals and market access.
• Economic fluctuations that may influence healthcare spending and demand for products.

What Are the Growth Opportunities for GIFOF?

• Expansion in Emerging Markets: Grifols aims to penetrate emerging markets, where the demand for plasma-derived therapies is increasing due to rising healthcare expenditures. The global plasma market is projected to reach $45 billion by 2028, providing Grifols with significant growth potential in regions like Asia and Latin America over the next five years.
• Innovative Product Development: The company is investing in R&D to develop new therapies, particularly in immunology and hematology. With the global immunoglobulin market expected to grow at a CAGR of 9% from 2023 to 2028, Grifols' focus on innovation can enhance its product offerings and market share.
• Strategic Partnerships: Grifols continues to seek collaborations to enhance its research capabilities and expand its product portfolio. By leveraging partnerships, such as the one with Mondragon, the company can accelerate the development of new therapies and improve operational efficiencies, driving future growth.
• Increased Demand for Diagnostic Products: The Diagnostic division is poised for growth due to the rising need for accurate diagnostic solutions, particularly in infectious diseases and chronic conditions. The global diagnostics market is projected to grow to $200 billion by 2026, providing Grifols with opportunities to expand its diagnostic offerings.
• Focus on Sustainability: Grifols is committed to sustainable practices, which can enhance its brand reputation and attract environmentally conscious investors. By implementing eco-friendly initiatives in its manufacturing processes, the company can differentiate itself in the competitive landscape and appeal to a broader customer base.

What Are GIFOF's Competitive Advantages?

• Established reputation and expertise in plasma-derived therapies.
• Strong R&D capabilities leading to innovative product development.
• Diverse product portfolio addressing various medical conditions.
• Strategic partnerships enhancing operational and technological capabilities.
• Global presence with a wide customer base across multiple regions.

What Does GIFOF Do?

Founded in 1940, Grifols, S.A. has established itself as a leading global healthcare company headquartered in Barcelona, Spain. The company specializes in the procurement, manufacture, preparation, and sale of therapeutic products, primarily focusing on hemoderivatives. Grifols operates through several divisions, including Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience division is particularly noteworthy, as it researches, develops, produces, and markets plasma-derived medicines and innovative solutions for treating chronic, rare, and life-threatening diseases. Its product offerings include immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division complements this by providing non-biological pharmaceutical products, medical supplies, clinical nutrition, intravenous therapy, and medical devices. Additionally, the Diagnostic division focuses on developing diagnostic products that span the healthcare continuum, serving professionals in prevention, screening, diagnosis, and treatment monitoring. The Bio Supplies division supplies biological materials for life-science research and clinical trials. Grifols serves a diverse customer base, including public and private healthcare providers, wholesalers, distributors, blood banks, and national health systems, ensuring its products are widely accessible. The company also engages in strategic collaborations, such as its technology agreement with Mondragon, to enhance its research and development capabilities.

What Products and Services Does GIFOF Offer?

• Procure and manufacture therapeutic products, primarily hemoderivatives.
• Develop plasma-derived medicines for chronic and rare diseases.
• Provide non-biological pharmaceutical products and medical supplies.
• Research and commercialize diagnostic products across the healthcare continuum.
• Supply biological materials for life-science research and clinical trials.
• Serve a diverse range of customers including hospitals, distributors, and national health systems.

How Does GIFOF Make Money?

• Generate revenue through the sale of plasma-derived therapies and diagnostic products.
• Engage in R&D to innovate and expand product offerings.
• Utilize strategic partnerships to enhance operational capabilities and market reach.
• Leverage economies of scale in manufacturing to improve profit margins.
• Serve both public and private healthcare sectors to diversify revenue streams.

What Industry Does GIFOF Operate In?

The healthcare industry, particularly the drug manufacturing sector, is experiencing robust growth, driven by an aging population and increasing prevalence of chronic diseases. The global plasma-derived therapies market is expected to expand significantly, with a projected CAGR of approximately 8% over the next five years. Grifols, S.A. is well-positioned within this landscape, leveraging its extensive experience and established product lines to capture market share. The competitive landscape includes notable players such as Recordati Industria Chimica e Farmaceutica S.p.A., Demant A/S, Kyowa Kirin Co., Ltd., Ono Pharmaceutical Co., Ltd., and Eisai Co., Ltd., each contributing to a dynamic environment characterized by innovation and regulatory challenges.

Who Are GIFOF's Key Customers?

• Public and private healthcare providers.
• Wholesalers and distributors of medical products.
• Blood banks and national health systems.
• Hospitals and care institutions.
• Research organizations and clinical trial sponsors.

Grifols, S.A. Financial Trajectory

Grifols, S.A. (GIFOF) reported $1.87B in revenue for Q2 2026, reflecting 9.8% growth compared to the prior quarter. The company recorded net income of $154.0M, with diluted EPS of $0.23. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, GIFOF averaged $0.17 in diluted EPS.

Company Profile

Grifols, S.A. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Barcelona, ES. The company is led by CEO Jose Ignacio Abia Buenache. GIFOF has traded publicly since 2013.

How Grifols, S.A. Is Valued

Grifols, S.A. carries a market capitalization of $8.70B, placing it in the mid-cap category. Relative to its peer group, GIFOF's quantitative score of 52/100 is roughly in line with the peer average of 57/100.

Return on equity for Grifols, S.A. stands at 7.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.1%, showing how much profit it generates from its asset base. GIFOF trades at a trailing price-to-earnings ratio of 14.74, below the Healthcare sector average of ~23x. Its free cash flow yield is 12.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.47 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.8%, the inverse of the P/E and a quick read on earnings relative to price.

Grifols, S.A.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.13 places it in the distress zone, a signal of elevated financial risk.

Grifols, S.A. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 0.8% below estimates on average.

Wall Street analysts project Grifols, S.A. revenue of about $7.68B for fiscal 2026, with EPS near $0.84. The estimate reflects 11 contributing analysts.

GIFOF Financials

GIFOF Latest News

No recent news available for GIFOF.

GIFOF Analyst Consensus

GIFOF MoonshotScore

What Investors Ask About Grifols, S.A. (GIFOF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources